Project Grant R01CA298343
Award Date
4/15/25
Completion Date
3/31/30
Dollars Obligated
$571K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $400,000 to Cancer Targeted Technology LLC to develop an innovative PSMA-targeted small molecule prodrug for the treatment of prostate cancer. The goal is to create a novel therapeutic that uses a cancer-specific biomarker, PSMA, to deliver a potent drug payload (monomethyl auristatin E) directly to prostate tumor cells while minimizing toxicity to healthy tissues....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Washington State University (WSU) provides $393,401 to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The key objectives are to: Assess the spatio-temporal cargo release of a PSMA-targeted SMDPC (small-molecule dual probe conjugate) in prostate tumor cells....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $799,962 to Tripill Biotechnology, Corp. to develop and validate a novel therapeutic PSMA-targeted agent for the treatment of prostate cancer. The goal is to create a radiolabeled PSMA agent that can selectively reduce radiation exposure to the salivary glands while maintaining high tumor uptake, thereby improving the therapeutic window for PSMA-targeted radiotherapies....
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $692,072 to The University of Texas Southwestern Medical Center to develop a novel theranostic platform for managing aggressive subtypes of prostate cancer. The key products and services to be delivered under this 5-year grant include: Synthesizing PSMA-targeted poly(amidoamine) (PAMAM) dendrimer-based theranostic agents that can enable specific targeting, PET/CT...
The National Cancer Institute (NCI) awarded a $549,357 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to conduct research on regulating the androgen receptor (AR) in prostate cancer. The key objectives of the 5-year project are: Determine the mechanism by which the long non-coding RNA NXTAR is suppressed in castration-resistant prostate cancers (CRPCs). Synthesize PSMA-targeted nanoparticles loaded with the NXTAR-N5 oligonucleotide, the ACK1...
This $624,001 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel class of molecules called Multivalent Peptoid Conjugates (MPCs) that can potently antagonize the androgen receptor (AR) and stop the growth of prostate cancer cells resistant to standard anti-androgen treatments. The research will investigate how MPCs can promote a unique AR conformation that alters gene expression patterns, leading to inhibition of prostate...
This Project Grant award of $160,167.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a peptide drug conjugate as a bone-targeted therapy for bone metastatic prostate cancer. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, and will fund research activities at the cancer center from September 1, 2023 through August 24, 2024. The project...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University to conduct research aimed at enhancing the efficacy of radiopharmaceutical therapy for prostate cancer (PC) and renal cell carcinoma (RCC). The research will systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy on glutaminolysis, a critical metabolic pathway in these cancer...
This federal Project Grant award for $472,458, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at the University of Texas Southwestern Medical Center to investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine phenotype. The key goals are to: 1) examine how anti-androgen therapy influences PTPN1 expression, 2) uncover the regulatory...
The National Cancer Institute (NCI) awarded a $422,874 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to the University of Connecticut Health Center (UCHC) to develop a well-defined in vitro model that mimics the bone-tumor microenvironment of metastatic prostate cancer. The goal is to create a flexible 3D bioprinted tumor microenvironment model that can serve as a preclinical screening platform to enhance the development of novel therapeutic agents. As part of this...